Wegovy Expands Globally With European Pill Approval, Indian Liver Disease Indication, and Higher Dose Options

# Podcast Episode Description **Wegovy's Big Expansion: New Pill Approval, MASH Treatment in India, and Safety Questions Explained** Wegovy is having a landmark moment — and this episode breaks down everything you need to know. From a historic European Commission approval of the first-ever oral GLP-1 weight loss pill to a game-changing new use in India for treating liver disease, Novo Nordisk is rapidly transforming Wegovy from a single injectable drug into a multi-product global platform. In this episode, we cover: ✅ **The first oral Wegovy pill approved in the EU** — 25mg semaglutide tablet showing ~17% average weight loss in trials, compared to 3% for placebo ✅ **A new higher-dose 7.2mg Wegovy injection** approved in Europe for patients needing stronger weight loss results ✅ **India's landmark approval** of Wegovy injection for MASH (metabolic dysfunction-associated steatohepatitis), a serious fatty liver disease — making it the first GLP-1 therapy approved for this condition in India ✅ **Safety updates you need to know**, including a potential link between Wegovy and a rare eye condition (ischemic optic neuropathy), plus new FDA findings that clear GLP-1 drugs of suicidal ideation risk ✅ **Supply chain relief** — Wegovy shortages have officially eased, according to FDA data ✅ **A new Medicare bridge program** launching in 2026 that could reshape insurance access to Wegovy for weight management ✅ **How Wegovy stacks up** against a growing wave of competing oral obesity drugs entering the market Whether you're a patient, healthcare provider, investor, or just curious about the future of obesity medicine, this episode unpacks why Wegovy continues to dominate headlines — and what its expansion means for pricing, competition, and patient access worldwide. **Perfect for listeners interested in:** pharmaceutical news, obesity treatment, Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai